Suzanne V Arnold1, Khaja M Chinnakondepalli1, John A Spertus1, Elizabeth A Magnuson1, Suzanne J Baron1, Saibal Kar2, D Scott Lim3, Jacob M Mishell4, William T Abraham5, JoAnn A Lindenfeld6, Michael J Mack7, Gregg W Stone8, David J Cohen9. 1. Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, Missouri. 2. Cedars-Sinai Medical Center, Los Angeles, California. 3. University of Virginia, Charlottesville, Virginia. 4. Kaiser Permanente-San Francisco Hospital, San Francisco, California. 5. Ohio State University, Columbus, Ohio. 6. Vanderbilt Heart and Vascular Institute, Nashville, Tennessee. 7. Baylor Scott and White Health, Plano, Texas. 8. New York-Presbyterian Hospital and Cardiovascular Research Foundation, New York, New York. 9. Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, Missouri. Electronic address: dcohen@saint-lukes.org.
Abstract
BACKGROUND: In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial, transcatheter mitral valve repair (TMVr) led to reduced heart failure (HF) hospitalizations and improved survival in patients with symptomatic HF and 3+ to 4+ secondary mitral regurgitation (MR) on maximally-tolerated medical therapy. Given the advanced age and comorbidities of these patients, improvement in health status is also an important treatment goal. OBJECTIVES: The purpose of this study was to understand the health status outcomes of patients with HF and 3+ to 4+ secondary MR treated with TMVr versus standard care. METHODS: The COAPT trial randomized patients with HF and 3+ to 4+ secondary MR to TMVr (n = 302) or standard care (n = 312). Health status was assessed at baseline and at 1, 6, 12, and 24 months with the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the SF-36 health status survey. The primary health status endpoint was the KCCQ overall summary score (KCCQ-OS; range 0 to 100; higher = better; minimum clinically important difference = 5 points). RESULTS: At baseline, patients had substantially impaired health status (mean KCCQ-OS 52.4 ± 23.0). While health status was unchanged over time in the standard care arm, patients randomized to TMVr demonstrated substantial improvement in the KCCQ-OS at 1 month (mean between-group difference 15.9 points; 95% confidence interval [CI]: 12.3 to 19.5 points), with only slight attenuation of this benefit through 24 months (mean between-group difference 12.8 points; 95% CI: 7.5 to 18.2 points). At 24 months, 36.4% of TMVr patients were alive with a moderately large (≥10-point) improvement versus 16.6% of standard care patients (p < 0.001), for a number needed to treat of 5.1 patients (95% CI: 3.6 to 8.7 patients). TMVr patients also reported better generic health status at each timepoint (24-month mean difference in SF-36 summary scores: physical 3.6 points; 95% CI: 1.4 to 5.8 points; mental 3.6 points; 95% CI: 0.8 to 6.4 points). CONCLUSIONS: Among patients with symptomatic HF and 3+ to 4+ secondary MR receiving maximally-tolerated medical therapy, edge-to-edge TMVr resulted in substantial early and sustained health status improvement compared with medical therapy alone. (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation [The COAPT Trial] [COAPT]; NCT01626079).
RCT Entities:
BACKGROUND: In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial, transcatheter mitral valve repair (TMVr) led to reduced heart failure (HF) hospitalizations and improved survival in patients with symptomatic HF and 3+ to 4+ secondary mitral regurgitation (MR) on maximally-tolerated medical therapy. Given the advanced age and comorbidities of these patients, improvement in health status is also an important treatment goal. OBJECTIVES: The purpose of this study was to understand the health status outcomes of patients with HF and 3+ to 4+ secondary MR treated with TMVr versus standard care. METHODS: The COAPT trial randomized patients with HF and 3+ to 4+ secondary MR to TMVr (n = 302) or standard care (n = 312). Health status was assessed at baseline and at 1, 6, 12, and 24 months with the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the SF-36 health status survey. The primary health status endpoint was the KCCQ overall summary score (KCCQ-OS; range 0 to 100; higher = better; minimum clinically important difference = 5 points). RESULTS: At baseline, patients had substantially impaired health status (mean KCCQ-OS 52.4 ± 23.0). While health status was unchanged over time in the standard care arm, patients randomized to TMVr demonstrated substantial improvement in the KCCQ-OS at 1 month (mean between-group difference 15.9 points; 95% confidence interval [CI]: 12.3 to 19.5 points), with only slight attenuation of this benefit through 24 months (mean between-group difference 12.8 points; 95% CI: 7.5 to 18.2 points). At 24 months, 36.4% of TMVrpatients were alive with a moderately large (≥10-point) improvement versus 16.6% of standard care patients (p < 0.001), for a number needed to treat of 5.1 patients (95% CI: 3.6 to 8.7 patients). TMVrpatients also reported better generic health status at each timepoint (24-month mean difference in SF-36 summary scores: physical 3.6 points; 95% CI: 1.4 to 5.8 points; mental 3.6 points; 95% CI: 0.8 to 6.4 points). CONCLUSIONS: Among patients with symptomatic HF and 3+ to 4+ secondary MR receiving maximally-tolerated medical therapy, edge-to-edge TMVr resulted in substantial early and sustained health status improvement compared with medical therapy alone. (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart FailurePatients With Functional Mitral Regurgitation [The COAPT Trial] [COAPT]; NCT01626079).
Authors: John Spertus; Eric Peterson; Mark W Conard; Paul A Heidenreich; Harlan M Krumholz; Philip Jones; Peter A McCullough; Ileana Pina; Joseph Tooley; William S Weintraub; John S Rumsfeld Journal: Am Heart J Date: 2005-10 Impact factor: 4.749
Authors: Francesco Maisano; Olaf Franzen; Stephan Baldus; Ulrich Schäfer; Jörg Hausleiter; Christian Butter; Gian Paolo Ussia; Horst Sievert; Gert Richardt; Julian D Widder; Tiziano Moccetti; Wolfgang Schillinger Journal: J Am Coll Cardiol Date: 2013-06-07 Impact factor: 24.094
Authors: Gabriel E Soto; Philip Jones; William S Weintraub; Harlan M Krumholz; John A Spertus Journal: Circulation Date: 2004-07-19 Impact factor: 29.690
Authors: Paul A Heidenreich; John A Spertus; Philip G Jones; William S Weintraub; John S Rumsfeld; Saif S Rathore; Eric D Peterson; Frederick A Masoudi; Harlan M Krumholz; Edward P Havranek; Mark W Conard; Randall E Williams Journal: J Am Coll Cardiol Date: 2006-01-26 Impact factor: 24.094
Authors: Mikhail Kosiborod; Gabriel E Soto; Philip G Jones; Harlan M Krumholz; William S Weintraub; Prakash Deedwania; John A Spertus Journal: Circulation Date: 2007-04-09 Impact factor: 29.690
Authors: Lynne W Stevenson; Anne S Hellkamp; Carl V Leier; George Sopko; Todd Koelling; J Wayne Warnica; William T Abraham; Edward K Kasper; Joseph G Rogers; Robert M Califf; Elizabeth E Schramm; Christopher M O'Connor Journal: J Am Coll Cardiol Date: 2008-11-18 Impact factor: 24.094
Authors: Annetine C Gelijns; Alan J Moskowitz; Patrick T O'Gara; Gennaro Giustino; Michael J Mack; Donna M Mancini; Emilia Bagiella; Judy Hung; Gorav Ailawadi; Martin B Leon; Michael A Acker; John H Alexander; Neal W Dickert; Wendy C Taddei-Peters; Marissa A Miller Journal: J Thorac Cardiovasc Surg Date: 2020-03-21 Impact factor: 5.209
Authors: Ali O Malik; Adnan K Chhatriwalla; John Saxon; Vittal Hejjaji; Amanda Stebbins; Philip G Jones; David J Cohen; Suzanne V Arnold; Sreekanth Vemulapalli; Zachary K Wegermann; Andrzej Kosinski; John A Spertus Journal: Circ Cardiovasc Qual Outcomes Date: 2020-12-07
Authors: Toby Rogers; Adam B Greenbaum; Vasilis C Babaliaros; Jason R Foerst; Jaffar M Khan; Christopher G Bruce; Annette M Stine; Lowell F Satler; Emily Perdoncin; Patrick T Gleason; John C Lisko; Xin Tian; Rui Miao; Vandana Sachdev; Marcus Y Chen; Robert J Lederman Journal: JACC Cardiovasc Interv Date: 2022-06-27 Impact factor: 11.075